466 related articles for article (PubMed ID: 19368729)
1. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Lee N; Woodrum CL; Nobil AM; Rauktys AE; Messina MP; Dabora SL
BMC Pharmacol; 2009 Apr; 9():8. PubMed ID: 19368729
[TBL] [Abstract][Full Text] [Related]
2. Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.
Woodrum C; Nobil A; Dabora SL
J Transl Med; 2010 Feb; 8():14. PubMed ID: 20146790
[TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779.
Messina MP; Rauktys A; Lee L; Dabora SL
BMC Pharmacol; 2007 Nov; 7():14. PubMed ID: 17986349
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.
Lee L; Sudentas P; Donohue B; Asrican K; Worku A; Walker V; Sun Y; Schmidt K; Albert MS; El-Hashemite N; Lader AS; Onda H; Zhang H; Kwiatkowski DJ; Dabora SL
Genes Chromosomes Cancer; 2005 Mar; 42(3):213-27. PubMed ID: 15578690
[TBL] [Abstract][Full Text] [Related]
5. Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Finlay GA; Malhowski AJ; Polizzi K; Malinowska-Kolodziej I; Kwiatkowski DJ
Mol Cancer Ther; 2009 Jul; 8(7):1799-807. PubMed ID: 19584242
[TBL] [Abstract][Full Text] [Related]
6. Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex.
Lee L; Sudentas P; Dabora SL
Genes Chromosomes Cancer; 2006 Oct; 45(10):933-44. PubMed ID: 16845661
[TBL] [Abstract][Full Text] [Related]
7. Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2
Yang J; Samsel PA; Narov K; Jones A; Gallacher D; Gallacher J; Sampson JR; Shen MH
Neoplasia; 2017 Feb; 19(2):112-120. PubMed ID: 28092822
[TBL] [Abstract][Full Text] [Related]
8. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
9. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
[TBL] [Abstract][Full Text] [Related]
12. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis.
Guo Y; Kwiatkowski DJ
Mol Cancer Res; 2013 May; 11(5):467-73. PubMed ID: 23386687
[TBL] [Abstract][Full Text] [Related]
13. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.
Meikle L; Pollizzi K; Egnor A; Kramvis I; Lane H; Sahin M; Kwiatkowski DJ
J Neurosci; 2008 May; 28(21):5422-32. PubMed ID: 18495876
[TBL] [Abstract][Full Text] [Related]
14. The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex.
Way SW; Rozas NS; Wu HC; McKenna J; Reith RM; Hashmi SS; Dash PK; Gambello MJ
Hum Mol Genet; 2012 Jul; 21(14):3226-36. PubMed ID: 22532572
[TBL] [Abstract][Full Text] [Related]
15. cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.
Cohen JD; Tham KY; Mastrandrea NJ; Gallegos AC; Monks TJ; Lau SS
Toxicol Sci; 2011 Aug; 122(2):361-71. PubMed ID: 21693435
[TBL] [Abstract][Full Text] [Related]
16. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.
Peng H; Liu J; Sun Q; Chen R; Wang Y; Duan J; Li C; Li B; Jing Y; Chen X; Mao Q; Xu KF; Walker CL; Li J; Wang J; Zhang H
Oncogene; 2013 Sep; 32(39):4702-11. PubMed ID: 23108404
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.
Samuels JA
Clin J Am Soc Nephrol; 2017 Jul; 12(7):1196-1202. PubMed ID: 28302901
[TBL] [Abstract][Full Text] [Related]
18. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent.
Parkhitko A; Myachina F; Morrison TA; Hindi KM; Auricchio N; Karbowniczek M; Wu JJ; Finkel T; Kwiatkowski DJ; Yu JJ; Henske EP
Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12455-60. PubMed ID: 21746920
[TBL] [Abstract][Full Text] [Related]
19. A vascular model of Tsc1 deficiency accelerates renal tumor formation with accompanying hemangiosarcomas.
Leech JD; Lammers SH; Goldman S; Auricchio N; Bronson RT; Kwiatkowski DJ; Sahin M
Mol Cancer Res; 2015 Mar; 13(3):548-55. PubMed ID: 25548102
[TBL] [Abstract][Full Text] [Related]
20. Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis.
Pollizzi K; Malinowska-Kolodziej I; Stumm M; Lane H; Kwiatkowski D
Mol Cancer; 2009 Jun; 8():38. PubMed ID: 19527517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]